You told me to pipe down in the Gaba thread, and it also fulfills a New Year resolution I made to Baron, that I would try to tone down my silly video analogy posts in threads where they do not belong. Good to see you are having fun though, letting loose a little. I like that side of you.
I thought they say “Don’t frown, average down” That’s what I did with DIS, $158-$153! It’s not a trade” It’s a investment now. Lying to myself. I got screwed on GOCO, Screw Joe Namath!
Yeah, we do. I post my shit each week. Let's see some of your pain. I've always wondered how bad it might go for you when you have a bad day/week/whatever. We can be brothers-in-arms in pain?
Totally agree. Felt that way Tuesday. It made a liar out of me. As always, just a day or so early. No biggie though. We've learned to plan for that.
GBA PRESENTS: YMR YOUR MORNING REVIEW Piper Sandler a buyer of KnowBe4 into Q4 results 06:10 KNBE Piper Sandler analyst Rob Owens is a buyer of KnowBe4 shares into the company's Q4 results and keeps an Overweight rating on the name with a $31 price target. KnowBe4's broadening platform, expanding total addressable market and "consistent rule of 60+ execution" set it up well into the quarter and 2022, Owens tells investors in a research note. OpGen publishes trial results from 'Acuitas AMR Gene Panel' multicenter study 16:47 OPGN OpGen the release of a new peer-reviewed journal publication that demonstrates that the Acuitas AMR Gene Panel accurately detects and differentiates 28 genetic antimicrobial resistance markers performed on isolated colonies from 26 different pathogens including Pseudomonas aeruginosa, select members of Enterobacterales, and Enterococcus faecalis, and it associates AMR genes with not susceptible antimicrobial susceptibility results for up to 9 antimicrobial classes or subclasses. OpGen's clinical trial used for the FDA submission of the Acuitas AMR Gene Panel was conducted at four U.S. study sites and included testing of 1,224 de-identified stocks created from 584 retrospectively collected isolates and 83 prospectively collected clinical isolates. The Acuitas AMR Gene Panel results were compared with a combined reference standard including whole genome sequencing , organism identification and phenotypic antimicrobial susceptibility testing using standard of care microbiology culture. The results of this study have now been published in the Journal of Clinical Microbiology and the authors found that the Acuitas AMR Gene Panel is capable of detecting and differentiating a broad range of 28 AMR markers that can be associated with up to 9 antimicrobial classes from cultured isolates of Pseudomonas aeruginosa, select members of Enterobacterales, and Enterococcus faecalis with greater than or equal to 94.4% Positive Percent Agreement and greater than or equal to 96.5% Negative Percent Agreement as compared with a composite reference standard, including WGS, in just 2.5 hours. Mr. Cooper GAAP EPS of $2.01 beats by $0.74, revenue of $625M beats by $74.22M Feb. 11, 2022 7:09 AM ETMr. Cooper Group Inc. (COOP) Mr. Cooper(NASDAQ:COOP):press releaseQ4 GAAP EPS of $2.01beats by $0.74. Revenue of $625M (-27.3% Y/Y)beats by $74.22M. Zendesk(NYSE:ZEN)shares rose in after-hours trading after the customer service software company reported fourth-quarter results that were better than expected and it rejected a takeover offer from private equity. The San Francisco-based Zendesk said it earned an adjusted 17 cents a share on $375.4 million in revenue for the period, up 32% year-over-year. A consensus of Wall Street analysts expected the company to earn 18 cents per share on $369.81 million in revenue. Zendesk shares rose slightly more than 1.5% to $116.04following the results. Led by Chief Executive Mikkel Svane, Zendesk also gave guidance for the quarter ending March 31, saying it expects revenue to be between $381 million and $387 million, with Non-GAAP operating income between $20 million and $26 million. It also provided full-year guidance, saying it expects to generate between $1.675 billion and $1.705 billion in sales, with non-GAAP operating income between $117 million and $137 million. Free cash flow for the full-year is expected to be between $165 million and $195 million. In addition, Zendesk said that it rejected an "unsolicited" bid from a consortium of private equity firms to acquire Zendesk in an all-cash transaction valued between $127 and $132 per share. Zendesk said the bid "significantly undervalues" the company. The company will hold a conference call at 5 p.m. EST to discuss the results. Earlier on on Thursday, it was reported that several private equity firms, including Thoma Bravo LP, were looking to acquire Zendesk. NBCUniversal may pull shows from Hulu in change of partnership with Disney - WSJ Life Time expands footprint in Dallas/Fort with opening of Luxury Athletic Resort in Frisco Feb. 11, 2022 6:43 AM ETLife Time Group Holdings, Inc. (LTH) Life Time(NYSE:LTH)hasopenedits tenth destination in the Dallas/Fort Metroplex. Life Time Frisco features 124,000 stunning square-feet of health andwellness spaces, and comprehensive programs and services designed to help people live healthy, active lives. The new resort features Life Time's signature upscale architecture and design. Life Time debuted in Dallas/Fort Worth in 2003 with the opening of its Plano location. Including Life Time Frisco, the Company now operates10 athletic resorts in the market.
Walk me through this - Life Time Group Holdings, Inc. (LTH) NYSE - NYSE Delayed Price. Currency in USD 16.61+0.14(+0.85%) At close: February 10 04:00PM EST 16.61+0.01(+0.06%) After hours:Feb 10, 04:01PM EST This is not that stock we almost bought... Xpo Fitness.... New Gym stk?